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Abstract
Background: Inflammation is implicated in causing diabetes. We tested whether transcription
factor 7 like-2 (TCF7L2) gene polymorphisms (rs12255372 and rs7903146), consistently associated
with type 2 diabetes, are associated with plasma concentrations of inflammatory markers before
and after three weeks of daily treatment with fenofibrate.
Methods: Men and women in the Genetics of Lipid-Lowering Drugs and Diet Network study (n
= 1025, age 49 ± 16 y) were included. All participants suspended use of lipid-lowering drugs for
three weeks and were then given 160 mg/day of fenofibrate for three weeks. Inflammatory markers
and lipids were measured before and after fenofibrate. ANOVA was used to test for differences
across TCF7L2 genotypes.
Results: Under the additive or dominant model, there were no significant differences (P > 0.05) in
the concentrations of inflammatory markers (hsCRP, IL-2, IL-6, TNF-α and MCP-1) across TCF7L2
genotypes in the period before or after treatment. For both rs12255372 and rs7903146,
homozygote T-allele carriers had significantly higher (P < 0.05) post-fenofibrate concentrations of
MCP-1 in the recessive model. No other significant associations were detected.
Conclusion: Overall these data show no association between TCF7L2 polymorphisms and the
inflammatory markers suggesting that the effects of TCF7L2 on diabetes may not be via
inflammation.
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Background
Two polymorphisms (rs12255372 and rs7903146) in the
transcription factor 7 like-2 (TCF7L2) gene have been
consistently associated with diabetes in various popula-
tions [1-3]. Diabetes is an inflammatory condition in
which up-regulation of inflammatory markers such as
tumor necrosis factor (TNF)-α leads to impaired insulin
signaling [4]. In vitro, TNF-α has been shown to enhance
the transcriptional activity of TCF7L2 leading to reduced
adipogenesis [5,6]. However, the sequence of events relat-
ing inflammation and TCF7L2 activity in vivo is not well
understood. There are no published reports on whether
the biological effects of TCF7L2 gene on diabetes are
partly via inflammation or whether inflammation alters
the effects of TCF7L2 on insulin secretion and other met-
abolic traits. Moreover how the potential association
between TCF7L2 and inflammatory markers may be mod-
ified by diet and other environmental exposures such as
fenofibrate is not known.
Materials and methods
The subjects were 1025 Caucasian men and women in the
Genetics of Lipid-Lowering Drugs and Diet Network
(GOLDN) family study with three-generational pedigrees
in two genetically homogeneous centers in Minneapolis,
MN and Salt Lake City, Utah [7]. The GOLDN study is part
of the PROgram for GENetic Interaction (PROGENI) Net-
work, a group of National Institutes of Health (NIH)-
funded family intervention studies focusing on gene-envi-
ronment interactions. The main aim of the GOLDN study
is to characterize the genetic basis of the variable response
of triglycerides to two environmental contexts, one that
raises triglycerides (dietary fat), and one that lowers trig-
lycerides (fenofibrate treatment). Men and women in this
study participated in a three week open-label clinical trial
that tested triglyceride responses to a high-fat milkshake
(83% fat and 700 kcal/m2) before and after three weeks of
daily treatment with 160 mg of micronized fenofibrate.
Habitual dietary intake was assessed with the National
Cancer Institute diet history questionnaire (DHQ) [8]
while data on medical history, physical activity and other
lifestyle variables such as alcohol intake were collected
using an interviewer-administered questionnaire.
Inflammatory markers
All inflammatory markers were measured in a central lab-
oratory. hsCRP was measured on the Hitachi 911 analyzer
using a latex particle enhanced immunoturbidimetric
assay (Kamiya Biomedical Company, Seattle, WA). Other
inflammatory markers including monocyte chemoattract-
ant protein-1 (MCP1), interleukin-2 (IL2) soluble recep-
tor-α, IL6 and TNF-α) were measured before and after
treatment with fenofibrate using ELISA methods (R&D
Systems Inc. Minneapolis, MN) as described elsewhere
[9]. Quality assurance measurements for these assays were
excellent and have been reported previously [10]. Briefly,
the reliability coefficients for hsCRP, MCP-1, IL2 receptor-
α, IL6 and TNF-α were 0.99, 0.91, 0.97, 0.92 and 0.76,
respectively.
Genotyping for TCF7L2 rs7903146 and rs12255372 
polymorphisms
DNA isolation, genotyping procedure and quality control
measures for rs7903146 and rs12255372 polymorphisms
have been reported [11]. Genotyping was successful in
99.7% of the samples for rs7903146 and in the whole
study population for rs12255372.
This study was approved by the institutional review
boards at the University of Alabama at Birmingham, Uni-
versity of Minnesota, University of Utah and Tufts Univer-
sity.
Statistical analysis
SAS Software version 9.1.3 (SAS Institute, Inc., Cary, NC)
was used for statistical analyses. From the 1328 men and
women in the GOLDN study, we excluded all subjects
with a self-reported history of kidney disease, Grave's dis-
ease, and those with missing data on major exposure var-
iables and potential confounders. The final data set
consists of 1025 subjects in 186 families that have com-
plete baseline measurements on inflammatory markers.
In this subset, 776 men and women completed the fenof-
ibrate trial and have complete data on both baseline and
post-fenofibrate measurements of inflammatory markers
and genotypes for rs7903146 polymorphism.
A subsample of unrelated subjects was used to test
TCF7L2 genotypes for departure from Hardy-Weinberg
Equilibrium. As an additional quality control measure we
performed Mendelian checks on the genotype data. Varia-
bles were checked for normality and where necessary they
were log- or square-root transformed. The significance of
differences in the distribution of inflammatory markers
and potential confounders by the TCF7L2 genotypes were
tested using an ANOVA model using the Mixed procedure
in SAS. This model adjusted for age, sex, field center,
smoking, physical activity, alcohol intake and pedigree.
Pedigree was included as a random effect to adjust for
familial relationships. Habitual diet, BMI and waist cir-
cumference were also tested as potential confounders or
intermediate variables in the TCF7L2-inflammation path-
way. We further tested whether there were significant
interactions between dietary variables and TCF7L2 poly-
morphisms and inflammatory markers.
Results
The frequencies for the CC, CT and TT genotypes in
rs7903146 polymorphism were 0.50, 0.39 and 0.11,
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respectively while they were 0.51, 0.39 and 0.11 for the
GG, GT and TT genotypes in rs12255372 polymorphism,
respectively. As showed previously in this [11] and other
studies [2], the two polymorphisms (rs7903146 and
rs12255372) are in strong linkage disequilibrium (D' =
0.9, r = 0.9). Thus the characteristics of the study popula-
tion are shown only by rs7903146 polymorphism (Table
1). There were not significant differences (P > 0.05) across
genotypes with regard to age, BMI, habitual diet, etc.
The distribution of inflammatory markers by TCF7L2 gen-
otypes is shown in Table 2. In an additive model, there
were no significant differences (P > 0.05) in the inflamma-
tory markers (CRP, IL-2, IL-6, TNF-α and MCP-1) across
TCF7L2 genotypes in the period before or after treatment
with fenofibrate. Further adjustment for waist circumfer-
ence or use of statins or other lipid-lowering drugs 4
weeks prior to the study did not change the significance of
the associations.
We further tested for associations between genotypes and
inflammatory markers using the dominant or recessive
genetic model. No associations (P > 0.05) were detected
under the dominant model. Under the recessive model we
found that homozygote carriers of the T allele in either
SNP had significantly higher (P < 0.05) post-fenofibrate
concentrations of MCP-1 before and after adjusting for
baseline MCP-1 concentrations, age, smoking, sex, field
center, alcohol use, physical activity and familial relation-
ships. The mean ± SD for the TT vs. CC+CT in rs7903146
were 197 ± 77 vs. 182 ± 98 pg/mL, respectively. The mean
± SD for the TT vs. GG+GT in rs12255372 were 197 ± 80
vs. 182 ± 98 pg/mL, respectively. No other significant
associations were detected.
The difference in the concentrations of inflammatory
markers (i.e., after treatment minus baseline measure-
ment) also did not significantly differ (P > 0.05) by
TCF7L2 genotypes (data not shown). These findings are
not likely to be confounded by diet or other lifestyle vari-
ables since these variables did not differ across genotypes
and did not significantly change the associations when
added to the multivariate mixed models. Furthermore we
did not detect any significant interactions between dietary
variables and TCF7L2 polymorphisms (data not shown).
The main dietary variables examined were intake of caf-
feine, total glycemic load, total carbohydrate, polyunsatu-
rated fat, trans fat, saturated fat and total energy.
Discussion
We have shown that TCF7L2 polymorphisms
(rs12255372 and rs7903146) that have been consistently
associated with type 2 diabetes are not significantly (P >
0.05) associated with any of the inflammatory markers in
analyses before treatment with fenofibrate. A part from
MCP-1 concentrations which were significantly higher (P
< 0.05) among homozygote carriers of the T-allele in
either SNP, there were no other significant associations
observed for inflammatory markers measured after treat-
ment with fenofibrate. These data suggest that the effects
of TCF7L2 on diabetes may not be via inflammation.
Although the findings from this study show a null associ-
ation between TCF7L2 polymorphisms and inflammatory
markers, they are important because there are no pub-
lished studies on the association between TCF7L2 poly-
morphisms and inflammatory markers. These data
support earlier studies that suggested impaired insulin
secretion but not insulin sensitivity [12] as the main
causal pathway for the relation between TCF7L2 gene and
risk for type 2 diabetes [13].
Table 1: Characteristics of the study population by TCF7L2 polymorphism (rs7903146)
TCF7L2 genotypes for rs7903146
Variable CC CT TT
n 514 398 113
Age (years) 48.7 (16.2) 48.8 (16.4) 48.5 (16.0)
Derived BMI (kg/m2) 28.4 (5.9) 28.3 (5.6) 28.0 (5.1)
Waist circumference (m) 96.1 (16.1) 97.2 (17.0) 96.7 (15.1)
Average systolic (mmHg) 114.4 (16.1) 116.1(17.0) 116.0 (16.4)
Average diastolic (mmHg) 67.6 (9.4) 68.6 (9.3) 68.7 (9.5)
Total dietary fat (% energy/d) 35.4 (7.0) 35.5 (6.3) 35.6 (7.1)
Dietary sat fat (% energy/d) 11.8 (2.7) 11.9 (2.6) 12.0 (2.9)
Dietary MUFA (% energy/d) 13.3 (2.9) 13.3 (2.6) 13.4 (2.8)
Dietary PUFA (% energy/d) 7.6 (2.2) 7.7 (2.0) 7.5 (2.2)
Dietary trans (% energy/d) 2.1 (0.6) 2.2 (0.6) 2.2 (0.7)
Dietary carbohydrate (% energy/d) 49.1 (8.5) 49.0 (7.9) 48.3 (9.2)
Dietary protein (% energy/d) 15.9 (2.9) 15.8 (2.7) 15.4 (3.2)
Caffeine (mg/d) 278 (439) 272 (413) 264 (380)
P > 0.05; TCF7L2 polymorphism rs7903146 is in strong LD (D' = 0.9) with rs12255372.
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Table 2: Concentrations of inflammatory markers by polymorphisms in the TCF7L2 genea
Variable rs12255372 (G>T) rs7903146 (C>T)
Before fenofibrate GG GT TT CC CT TT
n 512 390 115 514 398 113
CRP, mg/dL 0.23 (0.37) 0.25 (0.59) 0.33 (0.82) 0.23 (0.36) 0.25 (0.57) 0.31 (0.79)
IL-2 sR alpha, pg/mL 1014 (375) 1035 (353) 991 (332) 1021 (384) 1029 (350) 990 (324)
IL-6, pg/mL 2.04 (3.90) 1.88 (2.31) 1.88 (1.98) 2.10 (4.16) 1.74 (1.28) 2.00 (2.39)
TNF-alpha, pg/mL 3.25 (2.48) 3.73 (8.07) 3.35 (2.79) 3.28 (2.48) 3.68 (7.99) 3.36 (2.72)
MCP-1, pg/mL 208 (58) 212 (78) 205 (51) 209 (58) 210 (78) 207 (49)
After fenofibrate
n 373 300 89 373 307 96
hsCRP, mg/dL 0.22 (0.35) 0.29 (0.53) 0.30 (0.61) 0.22 (0.37) 0.30 (0.54) 0.25 (0.50)
IL-2 sR alpha, pg/mL 1161 (539) 1186 (580) 1086 (354) 1169 (541) 1186 (573) 1063 (336)
IL-6, pg/mL 2.22 (4.23) 2.24 (2.68) 1.86 (2.08) 2.24 (4.34) 2.12 (2.21) 1.99 (2.19)
TNF-alpha, pg/mL 3.52 (2.36) 3.99 (5.99) 3.64 (2.53) 3.55 (2.36) 3.96 (5.93) 3.58 (2.46)
MCP-1, pg/mL 179 (94) 186 (102) 197 (80) 179 (93) 187 (103) 197 (77)
a Values are means and SD; there were no significant differences across genotypes (P > 0.05).
